CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0737 (clinicaltrials.gov NCT No: NCT01787487)
Title:
EVALUATION OF RUXOLITINIB AND AZACYTIDINE COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME/ MYELOPROLIFERATIVE NEOPLASM
Principal Investigator:Naval Daver
Treatment Agent:Ruxolitinib
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
ruxolitinib and azacytidine can help to control myelofibrosis and
myeloproliferative neoplasm.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Ruxolitinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Incyte
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naval Daver
Dept:Leukemia
For Clinical Trial Enrollment:713-794-4392
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults